Navigation Links
Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
Date:9/17/2009

iscovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena has a broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, which includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the significance of the BLOSSOM and BLOOM results and the completion of the lorcaserin Phase 3 pivotal registration program; the development, advancement, therapeutic indication, tolerability, safety, selectivity and efficacy of lorcaserin; the protocol, design, scope, enrollment and other aspects of the lorcaserin trials; the engineering of weight management drug candidates; the FDA's guidance, process and requirements; the potential of the lorcaserin Phase 3 program and its results to satisfy the FDA's approval requirements, including with regard to efficacy and safety; the risk of developing valvulopathy; future activities, results and announcements relating to lorcaserin, including submitting an NDA for lorcaserin, working with the FDA during the review process, submitting the BLOOM-DM results as a supplement to the NDA, and commercializing lorcaserin; lorcaserin's commercial and other potential, including in managing weight, changing treatment, improving health and generating intere
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... HAYWARD, Calif. , May 24, 2013 Solta ... in the medical aesthetics market, today reported Dr. ... of the Company,s Board of Directors effective immediately.  Dr. Knowlton ... Medical and had served as a director since 1996. ... well as our management team, I would like to thank ...
(Date:5/24/2013)... , May 24, 2013  Auxilium Pharmaceuticals, Inc. ... management will participate in the Deutsche Bank Health Care ... Boston Waterfront Hotel.  Mr. Adrian Adams ... present an overview of the Company and its product ... 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) ...
(Date:5/24/2013)... England and BOSTON , ... GPCR drug discovery and development company, is pleased to announce that ... a Consultant to augment the Company,s business development capabilities in ... Usui has more than 15 years of experience in business development, ... at Perlegen Sciences, Inc., Roche Pharma ( Japan ), ...
Breaking Medicine Technology:Dr. Edward W. Knowlton Resigns as a Director of Solta Medical, Inc. 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2
... 2011 VIVUS, Inc. (NASDAQ: VVUS ) today ... the European Congress on Obesity (ECO) in Istanbul, Turkey.  ECO ... the Study of Obesity (EASO). ECO is regularly attended by ... considered to be the most important annual scientific event on ...
... and Anne Wojcicki announced a $50-million challenge spurring existing and ... to The Michael J. Fox Foundation for Parkinson,s Research (MJFF). ... new or increased gifts to The Michael J. Fox Foundation ... The Brin Wojcicki Challenge will bolster MJFF,s ongoing efforts to ...
Cached Medicine Technology:Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 2Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 3Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 4Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 5Brin Wojcicki Foundation Announces $50-Million Challenge Grant to Michael J. Fox Foundation to Spur Progress Toward Parkinson's Cure 2
(Date:5/25/2013)... Albany, New York (PRWEB) May 25, 2013 ... and substances which are used to detect and create ... available for test reading and are also known as ... of research, bioscience, diagnosis and education. , This market ... use of reagents in the field of therapeutics, growth ...
(Date:5/25/2013)... Idaho (PRWEB) May 25, 2013 A ... prevalent type of peripheral neuropathy. According to neuropathy expert ... , it is estimated that the disorder affects almost ... common complication arising from Diabetes. The high blood sugar ... Diabetes and patients suffering from it usually tend to ...
(Date:5/25/2013)... SATURDAY, May 25 (HealthDay News) -- Many viruses and ... rabies and leptospirosis -- a bacteria-borne illness than can ... lurking at dog parks, according to a veterinarian. ... water and even the air, said Dr. Susan Nelson, ... Health Center. "Many of these serious diseases can be ...
(Date:5/25/2013)... 2013 The report “Global Food ... Functions, Applications, Ingredients, Shell Materials, Packaging, & Geography: ... food encapsulation market with analysis and forecasting of ... identifies the driving and restraining factors for the ... opportunities, and challenges. The market is segmented and ...
(Date:5/25/2013)... Dallas, TX (PRWEB) May 25, 2013 ... between those who are carrying excessive weight and their ... that for many, simply losing weight can naturally relieve ... Medicine found that improvement in sleep quality was significantly ... this six month study dated November 6th, ...
Breaking Medicine News(10 mins):Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 3Health News:Diabetic Neuropathy treatment hits new grounds- Neuracel launches the complete natural treatment 2Health News:Hidden Dangers Dog Dog Parks 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2
... aura about cosmetic surgery that often hovers around expecting ... Medical Defence Union insurance group// has revealed that discontentment ... reasons for seeking compensation claims. , ,It is ... has been coughed up by the MDU in the ...
... beneficial as it increases the concentration, abstract reasoning and ... say these results must be interpreted with caution//. ... University Baptist Medical Center in the US studied more ... drink a moderate amount of alcohol have slightly higher ...
... those of SMS Medical College here, called off their ... copy of the Supreme Court verdict directing medicos to ... to work, their protest would continue with the support ... strike would continue to protest the proposed 27 percent ...
... federal government plans to spend in this financial year ... activities//. Among doubts on whether this enormous expenditure is ... indicated that the expenditure is paying off and is ... study that is now available on line is due ...
... in Finland to show the increased risk of ... after watching many current T.V//. The Finnish researchers ... exposure to adult-targeted programs, such as current affairs ... They also showed that passive exposure to TV ...
... to be issued after today's UN meet on AIDS, activists ... the epidemic that has claimed 25 million lives so far.// ... UN Secretary General Kofi Annan asked diplomats not to negotiate ... ,The UNGA's session hoped to arrive at a plan that ...
Cached Medicine News:Health News:New Study Conducted To Evaluate The Success Of The Federal governments Funds For HIV/AIDS 2Health News:TV Viewing Might Increase The Risk Of Sleeping Difficulties In Children’ 2
... pro Electronic Pipette is ideal for all ... easy-to-follow display, ergonomically-placed operating buttons, and various ... pipetting and diluting make this a lab ... of a manual pipette without any adverse ...
... provide a complete hematology profile, including a ... aggregation. Aggregation testing is based on performing ... platelet activation, using either collagen or ADP ... and no special sample preparation is required. ...
... A complete range of automatic systems for ... 1 mL of blood. With the introduction ... the clinical diagnostic market a truly revolutionary ... technical limitation associated with the traditional ESR ...
... range of automatic systems for performing erythrocyte ... of blood. With the introduction of the ... diagnostic market a truly revolutionary testing system ... associated with the traditional ESR techique.,By means ...
Medicine Products: